Amit Kumar Buys 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, July 10th. The stock was bought at an average cost of $3.04 per share, for a total transaction of $15,200.00. Following the purchase, the chief executive officer owned 635,812 shares in the company, valued at $1,932,868.48. This represents a 0.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, June 12th, Amit Kumar purchased 21,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Up 4.2%

NASDAQ ANIX opened at $3.19 on Wednesday. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46. The stock has a market cap of $108.52 million, a price-to-earnings ratio of -10.29 and a beta of 0.59. The business has a fifty day moving average of $2.80 and a 200-day moving average of $2.90.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. As a group, analysts anticipate that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANIX. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Finally, D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.50.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds have recently made changes to their positions in the stock. Segall Bryant & Hamill LLC acquired a new stake in shares of Anixa Biosciences during the 1st quarter worth $45,000. Renaissance Technologies LLC boosted its holdings in Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after acquiring an additional 7,300 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in Anixa Biosciences by 96.2% in the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after acquiring an additional 25,000 shares during the last quarter. Virtu Financial LLC purchased a new stake in Anixa Biosciences during the fourth quarter valued at about $161,000. Finally, Millennium Management LLC purchased a new stake in Anixa Biosciences during the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.